Core Insights - On September 1, BGI Genomics experienced a decline of 1.56% with a trading volume of 349 million yuan [1] - As of June 30, BGI Genomics reported a revenue of 1.114 billion yuan for the first half of 2025, a year-on-year decrease of 7.90% [2] Financing and Margin Trading - On September 1, BGI Genomics had a financing buy-in amount of 40.41 million yuan and a net financing buy of 8.50 million yuan, with a total margin balance of 432 million yuan [1] - The current financing balance of 426 million yuan accounts for 2.83% of the circulating market value, indicating a high level compared to the past year [1] Shareholder and Institutional Holdings - As of June 30, the number of shareholders for BGI Genomics increased by 7.64% to 13,500, while the average circulating shares per person decreased by 7.09% to 15,766 shares [2] - The top ten circulating shareholders include notable ETFs, with the Huaxia SSE Sci-Tech 50 ETF holding 11.53 million shares, a decrease of 245,600 shares from the previous period [3]